Christopher Sullivan

2021

In 2021, Christopher Sullivan earned a total compensation of $627.6K as Chief Financial Officer and principal financial officer at Avalo Therapeutics.

Compensation breakdown

Non-Equity Incentive Plan$85,860
Option Awards$241,782
Salary$300,000
Total$627,642

Sullivan received $300K in salary, accounting for 48% of the total pay in 2021.

Sullivan also received $85.9K in non-equity incentive plan and $241.8K in option awards.

Rankings

In 2021, Christopher Sullivan's compensation ranked 10,199th out of 12,415 executives tracked by ExecPay. In other words, Sullivan earned more than 17.8% of executives.

ClassificationRankingPercentile
All
10,199
out of 12,415
18th
Division
Manufacturing
4,512
out of 5,505
18th
Major group
Chemicals And Allied Products
2,016
out of 2,375
15th
Industry group
Drugs
1,787
out of 2,096
15th
Industry
Pharmaceutical Preparations
1,328
out of 1,546
14th
Source: SEC filing on October 19, 2023.

Sullivan's colleagues

We found four more compensation records of executives who worked with Christopher Sullivan at Avalo Therapeutics in 2021.

2021

Michael Cola

Avalo Therapeutics

Chief Executive Officer

2021

Schond Greenway

Avalo Therapeutics

Chief Financial Officer

2021

H Wilkins

Avalo Therapeutics

Chief Medical Officer

2021

Garry Neil

Avalo Therapeutics

Chief Executive Officer

News

You may also like